Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market. Academic Article uri icon

Overview

abstract

  • This cross-sectional study describes changes in annual Medicare Part B spending for biologic drugs after biosimilar entry, focusing on the first 4 products to experience biosimilar competition: filgrastim, infliximab, epoetin alpha, and pegfilgrastim.

publication date

  • September 17, 2021

Research

keywords

  • Biosimilar Pharmaceuticals
  • Medicare Part B

Identity

PubMed Central ID

  • PMC8796923

Scopus Document Identifier

  • 85147571537

Digital Object Identifier (DOI)

  • 10.1377/hblog20190405.396631/full/

PubMed ID

  • 35977178

Additional Document Info

volume

  • 2

issue

  • 9